PD-L1 protein levels have been found to be upregulated in NSCLC patients, and nowadays, checkpoint inhibitors that block the interaction between PD-1 and PD-L1 are routinely used in their clinical management [52,53,54,55]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.